基因编辑技术合作与授权协议（2016-2025）

本报告全面深入分析了基因编辑技术合作与授权协议，让您以前所未有的方式了解全球领先的生物製药公司签署的基因编辑技术相关协议。

这份经过全面修订和更新的报告详细介绍了2016年至2025年的基因编辑交易。

本报告详细分析了公司签署基因编辑协议的原因和方式。这些协议通常包含多个要素，涵盖合作研发到成果商业化等各个面向。

本报告涵盖合作研究、开发、探索和授权。

本报告包​​含自2016年以来公布的384项基因编辑交易的完整列表，其中包括可用的财务条款以及各方披露的实际基因编辑合作的在线记录链接。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的前几章概述了基因编辑领域的交易情况。

第一章概述了本报告。

第二章概述了自 2016 年以来的基因编辑交易情况。

第三章概述了自 2016 年以来主要的基因编辑交易，并依交易总额列出。

第四章提供了基因编辑领域交易活动最活跃的前 25 家公司的完整名单，以及简要概述和基因编辑交易及公开合约文件的完整清单。

第五章对自 2016 年 1 月以来已完成和已宣布的、且有公开合约文件的基因编辑交易进行了全面深入的审查。

第六章对自2016年1月以来签署和公布的基因编辑领域合作协议进行了全面深入的回顾。本章依所涵盖的具体基因编辑技术类型进行组织。

本报告也包含大量表格和图表，展示了自2016年以来基因编辑交易的趋势和活动。

此外，我们还提供了一个全面的合约目录，依公司名称（A-Z）、合约类型和治疗标靶进行组织。每个合约标题都透过网路连结指向合约记录的线上版本，并在可用的情况下指向合约文件，以便根据需要轻鬆存取每个合约文件。

主要优势

"基因编辑领域的研究合作与授权协议" 报告提供读者以下主要优势：

• 了解自 2016 年以来的交易趋势
• 查看基因编辑领域的合作与授权协议
• 基准分析 - 确定交易的市场价值
• 财务条款 - 首付款、里程碑付款、特许权使用费
• 依公司（A-Z）、协议类型和治疗领域列出交易
• 以价值为排名的热门交易
• 最活跃的交易撮合者
• 确定每笔交易的资产和条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作公司的适用性
• 节省数百小时的研究时间

范围

• "基因编辑合作与授权协议" 旨在帮助读者深入了解基因编辑领域以及全球领先的生物製药公司正在签署的协议结构。

本报告内容

• 生物製药产业基因编辑交易趋势
• 製药和生物技术公司基因编辑交易记录目录
• 依金额排名的主要基因编辑交易
• 最活跃的基因编辑授权协议公司
• "基因编辑合作与许可协议" 提供对现有协议记录的全面访问，包括合约文件（如有）。

对协议的分析有助于对以下方面进行尽职调查：

• 协议具体授予或选择哪些权利？
• 协议实际授予合作公司哪些权利？
• 授予了哪些独家经营权？
• 交易的付款结构是什么？
• 如何进行销售和付款审计？
• 合约期限是多久？
• 如何定义协议的关键条款？
• 如何处理和归属知识产权？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止协议？
• 如果所有权发生变更，会发生什么事？
• 如何约定转让许可和分包条款？
• 贵公司要求使用哪些标准条款？
• 哪些标准条款会因交易对手和交易类型而异？
• 贵公司必须遵守哪个司法管辖区的法律？

目录

摘要整理

第一章：引言

第二章：基因编辑交易趋势

• 引言
• 历年基因编辑交易
• 最活跃的基因编辑交易商
• 以交易类型划分的基因编辑交易
• 依治疗领域划分的基因编辑交易
• 依行业划分的基因编辑交易
• 基因编辑交易条款
  • 基因编辑交易的关键价值
  • 基因编辑交易中的预付款
  • 基因编辑交易中的里程碑付款
  • 基因编辑专利费率

第三章：基因编辑的关键要素交易

• 引言
• 以价值排名的顶级基因编辑交易

第四章 - 最活跃的基因编辑经销商

• 引言
• 最活跃的基因编辑经销商
• 最活跃的基因编辑经销商公司简介

第五章 - 基因编辑合约交易目录

• 引言
• 基因编辑合约交易目录

第六章 - 以技术类型划分的基因编辑交易

• 交易目录
• 依公司划分的基因编辑交易目录 (AZ)
• 以交易类型划分的基因编辑交易目录
• 依治疗领域划分的基因编辑交易目录
• 交易类型定义
• 关于研究公司
• 当前合作伙伴关係
• 当前合约
• 当前合作伙伴关係近期报告标题

Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene editing deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 384 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene editing dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.

Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Editing Collaboration and Licensing Deals includes:

• Trends in gene editing dealmaking in the biopharma industry
• Directory of gene editing deal records covering pharmaceutical and biotechnology
• The leading gene editing deals by value
• Most active gene editing licensing dealmakers
• Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

• 2.1. Introduction
• 2.2. Gene editing deals over the years
• 2.3. Most active gene editing dealmakers
• 2.4. Gene editing deals by deal type
• 2.5. Gene editing deals by therapy area
• 2.6. Gene editing deals by industry sector
• 2.7. Deal terms for gene editing deals
  • 2.7.1 Gene editing deals headline values
  • 2.7.2 Gene editing deal upfront payments
  • 2.7.3 Gene editing deal milestone payments
  • 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

• 3.1. Introduction
• 3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

• 4.1. Introduction
• 4.2. Most active gene editing dealmakers
• 4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

• Deal directory
• Deal directory - Gene editing deals by company A-Z
• Deal directory - Gene editing deals by deal type
• Deal directory - Gene editing deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene editing deals since 2016
• Figure 2: Active gene editing dealmaking activity - 2016 - 2025
• Figure 3: Gene editing deals by deal type since 2016
• Figure 4: Gene editing deals by therapy area since 2016
• Figure 5: Gene editing deals by industry sector since 2016
• Figure 6: Gene editing deals with a headline value
• Figure 7: Gene editing deals with an upfront value
• Figure 8: Gene editing deals with a milestone value
• Figure 9: Gene editing deals with a royalty rate value
• Figure 10: Top gene editing deals by value since 2016
• Figure 11: Most active gene editing dealmakers 2016 - 2025
• Figure 12: Gene editing deals by technology type since 2016